Literature DB >> 1631501

Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer.

H F Røhl1, H P Beuke.   

Abstract

Because it is well known that prostatic cancer is dependent on testosterone, and that dihydrotestosterone is the active mediator of the androgen action in the prostatic cell, we studied serum concentrations of testosterone and dihydrotestosterone in 84 patients with prostatic cancer, 40 of whom were treated by orchidectomy, and 44 who were not treated. There was a significant correlation between testosterone and dihydrotestosterone concentrations in the untreated group, but no correlation among the patients treated by orchidectomy. The results indicate that the effectiveness of orchidectomy as androgen withdrawal treatment in prostatic cancer should be assessed by measurement of both dihydrotestosterone and testosterone concentrations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1631501     DOI: 10.3109/00365599209180389

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  5 in total

1.  Goserelin versus leuprolide in the chemical castration of patients with prostate cancer.

Authors:  Élcio Dias Silva; Ubirajara Ferreira; Wagner Matheus; Eliney F Faria; Gustavo D Silva; Minori Saito; Auro A S de Souza; Azuil Laranjo; Otavio Clark; Luis Alberto Magna; Lísias Nogueira Castilho; Leonardo Oliveira Reis
Journal:  Int Urol Nephrol       Date:  2012-08       Impact factor: 2.370

Review 2.  Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.

Authors:  Bobby Shayegan; Frédéric Pouliot; Alan So; John Fernandes; Joseph Macri
Journal:  Can Urol Assoc J       Date:  2017-06       Impact factor: 1.862

3.  Effective testosterone suppression for prostate cancer: is there a best castration therapy?

Authors:  Leonard G Gomella
Journal:  Rev Urol       Date:  2009

4.  Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.

Authors:  Jaro Wex; Manpreet Sidhu; Isaac Odeyemi; Ahmed M Abou-Setta; Peny Retsa; Bertrand Tombal
Journal:  Clinicoecon Outcomes Res       Date:  2013-06-24

5.  Evaluation of degarelix in the management of prostate cancer.

Authors:  Hendrik Van Poppel
Journal:  Cancer Manag Res       Date:  2010-01-25       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.